Oxepanes

Medchemexpress LLC Benzoic acid, 4-[5-(4,7-dimethyl-2-benzofuranyl)-1,2,4-oxadiazol-3-yl]- | 1952276-71-9 | 98.9% | 334.33 | 50 MG

Small and Specialty Supplier Partner
Small and/or specialty supplier based on Federal laws and SBA requirements.
Learn More

KCL-286 (C286) is an orally active and brain-penetrant retinoic acid receptor (RAR) β2 agonist (EC50 = 1.9 nM). It activates RARβ2 in injured neurons, inducing axonal regeneration and modulating neuroinflammation and extracellular matrix molecules. It can also modulate the expression of chondroitin sulfate proteoglycans (CSPGs) by neuronal secretion of decorin, promoting myelination and aiding axonal growth.

• Targets RARβ2 with selectivity over RAR α and RAR γ.
• Activates RARβ2 in injured neurons.
• Induces axonal regeneration of spinal and sensory nerves.
• Modulates neuroinflammation and extracellular matrix molecules.
• Promotes myelination and aids axonal growth.
• Suitable for research in spinal cord injury and traumatic nerve injury.

Medchemexpress LLC 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid | 1952276-71-9 | 98.9% | 334.33 g·mol⁻1 | C19H14N2O4 | 5 MG

Small and Specialty Supplier Partner
Small and/or specialty supplier based on Federal laws and SBA requirements.
Learn More

KCL-286 (C286) is a potent, selective retinoic acid receptor beta-2 (RARβ2) agonist reported to be orally active and brain-penetrant (reported EC50 = 1.9 nM). It is intended for research use in in vitro and in vivo studies of retinoid signaling and neurological pharmacology. Characterization includes molecular formula C19H14N2O4, molecular weight 334.33 g·mol⁻1, and CAS 1952276-71-9.

• Potent RARβ2 agonist (EC50 = 1.9 nM).
• Orally active and brain-penetrant in reported studies.
• Suitable for in vitro and in vivo pharmacology studies.
• Characterized by molecular formula C19H14N2O4 and molecular weight 334.33 g·mol⁻1.
• Supplied as a high-purity research reagent (≈98.9% reported purity).